Search Browse Earnings

Korro Bio, Inc. — SlamSEC

Korro Bio, Inc.

Nasdaq:KRRO

Pharmaceutical Preparations·CAMBRIDGE, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$14.1M

-62.0% YoY

FY 2022

Adj. EBITDA

-$80.9M

-575.1% margin

FY 2024

Net Income

-$81.2M

-577.0% margin

FY 2024

EPS (Diluted)

-$53.08

FY 2024

Stock Price

$11.48

-6.8%

2026-03-10

52W Range

$5.20 – $55.89

P/E Ratio

-0.2x

Market Cap

$108.1M

Cash

$36.6M

FY 2024

Total Debt

$180,000

FY 2020

Net Cash

$36.4M

FY 2020

Enterprise Value

$71.7M

Debt / EBITDA

0.5x

FY 2022

EV / EBITDA

-0.9x

Employees

—